Skip to main content

Advertisement

SpringerLink
Log in

Cost-effectiveness of screening for coronary artery disease in asymptomatic patients with type 2 diabetes and additional atherogenic risk factors

  • Original Articles
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

Abstract

OBJECTIVE: Screening for coronary artery disease (CAD) in asymptomatic diabetic patients with two additional atherogenic risk factors has been recommended by the American College of Cardiology/American Diabetes Association, but its cost-effectiveness is yet to be determined. The present study aims to evaluate the cost-effectiveness of screening and determine acceptable strategies.

DESIGN: Cost-effectiveness analysis using a Markov model was performed from a societal perspective to measure the clinical benefit and economic consequences of CAD screening in asymptomatic men with diabetes and two additional atherogenic risk factors. We evaluated cohorts of patients stratified by different age groups, and 10 possible combination pairs of atherogenic risks. Incremental cost-effectiveness of no screening, exercise electrocardiography, exercise echocardiography, or exercise single-photon emission-tomography (SPECT) was calculated. Input data were obtained from the published literature. Outcomes were expressed as U.S. dollars per quality-adjusted life-year (QALY).

MEASUREMENTS AND MAIN RESULTS: Compared with no screening, incremental cost-effectiveness ratio of exercise electrocardiography was $41,600/QALY in 60-year-old asymptomatic diabetic men with hypertension and smoking, but was weakly dominated by exercise echocardiography. Exercise echocardiography was most cost-effective, with an incremental cost-effectiveness ratio of $40,800/QALY. Exercise SPECT was dominated by other strategies. Sensitivity analyses found that results varied depending on age, combination of additional atherogenic risk factors, and diagnostic test performance.

CONCLUSIONS: Incremental cost-effectiveness ratio of CAD screening in asymptomatic patients with diabetes and two or more additional atherogenic risk factors is shown to be acceptable from a societal perspective. Exercise echocardiography was the most cost-effective strategy, followed by exercise electrocardiography.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035–8.

    Article  PubMed  CAS  Google Scholar 

  2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–44.

    Article  PubMed  CAS  Google Scholar 

  3. Fuller JH. Mortality trends and causes of death in diabetic patients. Diabetes Metab. 1993;19:96–9.

    CAS  Google Scholar 

  4. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1987;30:123–31.

    Article  PubMed  CAS  Google Scholar 

  5. Jacoby RM, Nesto RW. Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. J Am Coll Cardiol. 1992;20:736–44.

    Article  PubMed  CAS  Google Scholar 

  6. Fava S, Azzopardi J, Muscat HA, Fenech FF. Factors that influence outcome in diabetic subjects with myocardial infarction. Diabetes Care. 1993;16:1615–8.

    Article  PubMed  CAS  Google Scholar 

  7. Langer A, Freeman MR, Josse RG, Steiner G, Armstrong PW. Detection of silent myocardial ischemia in diabetes mellitus. Am J Cardiol. 1991;67:1073–8.

    Article  PubMed  CAS  Google Scholar 

  8. Rutter MK, McComb JM, Brady S, Marshall SM. Silent myocardial ischemia and microalbuminuria in asymptomatic subjects with non-insulin-dependent diabetes mellitus. Am J Cardiol. 1999;83:27–31.

    Article  PubMed  CAS  Google Scholar 

  9. Koistinen MJ, Huikuri HV, Korhonen UR, et al. Asymptomatic coronary artery disease in diabetes: relation to common risk factors, lipoproteins, apoproteins and apo E polymorphism. Acta Diabetol. 1994;31:210–4.

    Article  PubMed  CAS  Google Scholar 

  10. Naka M, Hiramatsu K, Aizawa T, et al. Silent myocardial ischemia in patients with non-insulin-dependent diabetes mellitus as judged by treadmill exercise testing and coronary angiography. Am Heart J. 1992;123:46–53.

    Article  PubMed  CAS  Google Scholar 

  11. Nesto RW, Watson FS, Kowalchuk GJ, et al. Silent myocardial ischemia and infarction in diabetics with peripheral vascular disease: assessment by dipyridamole thallium-201 scintigraphy. Am Heart J. 1990;120:1073–7.

    Article  Google Scholar 

  12. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes: 10–11 February 1998, Miami, Florida. American Diabetes Association. Diabetes Care. 1998;21:1551–9.

  13. Sox HC Jr, Littenberg B, Garber AM. The role of exercise testing in screening for coronary artery disease. Ann Intern Med. 1989;110:456–69.

    PubMed  Google Scholar 

  14. Cohn PF. Silent myocardial ischemia. Ann Intern Med. 1988;109:312–7.

    PubMed  CAS  Google Scholar 

  15. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322–38.

    Article  PubMed  CAS  Google Scholar 

  16. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health. 1987;77:1417–26.

    Article  PubMed  CAS  Google Scholar 

  17. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293–8.

    Article  PubMed  CAS  Google Scholar 

  18. Hunink MG, Goldman L, Tosteson AN, et al. The recent decline in mortality from coronary heart disease, 1980–1990. The effect of secular trends in risk factors and treatment. JAMA. 1997;277:535–42.

    Article  PubMed  CAS  Google Scholar 

  19. Airaksinen KE. Silent coronary artery disease in diabetes—a feature of autonomic neuropathy or accelerated atherosclerosis? Diabetologia. 2001;44:259–66.

    Article  PubMed  CAS  Google Scholar 

  20. Chaitman BR, Bourassa MG, Davis K, et al. Angiographic prevalence of high-risk coronary artery disease in patient subsets (CASS). Circulation. 1981;64:360–7.

    PubMed  CAS  Google Scholar 

  21. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–16.

    Article  PubMed  Google Scholar 

  22. Haffner SM. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004;27(suppl 1):S68-S71.

    Article  PubMed  Google Scholar 

  23. National Heart, Lung, and Blood Institute. Unpublished tabulation from the public use data tapes, National Health and Nutrition Examination Survey, 1971–1975, 1976–1980, 1988–1994. Hyattsville, Md: National Center for Health Statistics; 1999.

  24. Klesges RC, Debon M, Ray JW. Are self-reports of smoking rate biased? Evidence from the Second National Health and Nutrition Examination Survey. J Clin Epidemiol. 1995;48:1225–33.

    Article  PubMed  CAS  Google Scholar 

  25. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina). Circulation. 2003;107:149–58.

    Article  PubMed  Google Scholar 

  26. Zhang J, Yu KF. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690–1.

    Article  PubMed  CAS  Google Scholar 

  27. Alexander CM, Landsman PB, Teutsch SM. Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease. Am J Cardiol. 2000;86:897–902.

    Article  PubMed  CAS  Google Scholar 

  28. Gianrossi R, Detrano R, Mulvihill D, et al. Exercise-induced ST depression in the diagnosis of coronary artery disease. A meta-analysis. Circulation. 1989;80:87–98.

    PubMed  CAS  Google Scholar 

  29. Fleischmann KE, Hunink MG, Kuntz KM, Douglas PS. Exercise echocardiography or exercise SPECT imaging? A meta-analysis of diagnostic test performance. JAMA. 1998;280:913–20.

    Article  PubMed  CAS  Google Scholar 

  30. Johnson LW, Lozner EC, Johnson S, et al. Coronary arteriography 1984–1987: a report of the Registry of the Society for Cardiac Angiography and Interventions. I. Results and complications. Cathet Cardiovasc Diagn. 1989;17:5–10.

    Article  PubMed  CAS  Google Scholar 

  31. Holmes DR Jr, Holubkov R, Vlietstra RE, et al. Comparison of complications during percutaneous transluminal coronary angioplasty from 1977 to 1981 and from 1985 to 1986: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. J Am Coll Cardiol. 1988;12:1149–55.

    Article  PubMed  Google Scholar 

  32. Yusuf S, Zucker D, Chalmers TC. Ten-year results of the randomized controlled trials of coronary artery bypass graft surgery: tabular data compiled by the collaborative effort of the original trial investigators. Part 1 of 2. Online J Curr Clin Trials. 1994; document no. 144.

  33. Yusuf S, Zucker D, Chalmers TC. Ten-year results of the randomized controlled trials of coronary artery bypass graft surgery: tabular data compiled by the collaborative effort of the original trial investigators. Part 2 of 2. Online J Curr Clin Trials. 1994;document no. 145.

  34. Hannan EL, Kilburn H Jr, O’Donnell JF, Lukacik G, Shields EP. Adult open heart surgery in New York State. An analysis of risk factors and hospital mortality rates. JAMA. 1990;264:2768–74.

    Article  Google Scholar 

  35. Romeo F, Rosano GM, Martuscelli E, Valente A, Reale A. Characterization and long-term prognosis of patients with effort-induced silent myocardial ischaemia. Eur Heart J. 1992;13:457–63.

    PubMed  CAS  Google Scholar 

  36. Ekelund LG, Suchindran CM, McMahon RP, et al. Coronary heart disease morbidity and mortality in hypercholesterolemic men predicted from an exercise test: the Lipid Research Clinics Coronary Primary Prevention Trial. J Am Coll Cardiol. 1989;14:556–63.

    Article  PubMed  CAS  Google Scholar 

  37. Laukkanen JA, Kurl S, Lakka TA, et al. Exercise-induced silent myocardial ischemia and coronary morbidity and mortality in middle-aged men. J Am Coll Cardiol. 2001;38:72–9.

    Article  PubMed  CAS  Google Scholar 

  38. Arias E. United States Life Tables, 2002. National Vital Statistics Reports; vol. 51 no. 3. Hyattsville, Md: National Center for Health Statistics.

  39. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the “DEALE”). I. Validation of the method. Am J Med. 1982;73:883–8.

    Article  PubMed  CAS  Google Scholar 

  40. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the “DEALE”). II. Use in medical decision-making. Am J Med. 1982;73:889–97.

    Article  PubMed  CAS  Google Scholar 

  41. Drummond MF, Pang F. Modeling in economic evaluation. In: Drummond M, McGuire MA, eds. Economic Evaluation in Health Care: Merging Theory with Practice. Oxford, UK: Oxford University Press; 2001.

    Google Scholar 

  42. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists’ Collaboration. Lancet. 1994;344:563–70.

    Article  PubMed  CAS  Google Scholar 

  43. Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ. 1994;308:81–106.

    Google Scholar 

  44. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 2001;85:265–71.

    Article  PubMed  CAS  Google Scholar 

  45. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.

    PubMed  CAS  Google Scholar 

  46. Mark DB, Nelson CL, Califf RM, et al. Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation. 1994;89:2015–25.

    PubMed  CAS  Google Scholar 

  47. Pocock SJ, Henderson RA, Rickards AF, et al. Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery. Lancet. 1995;346:1184–9.

    Article  PubMed  CAS  Google Scholar 

  48. Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med. 2002;346:1800–6.

    Article  PubMed  Google Scholar 

  49. Myocardial infarction and mortality in the coronary artery surgery study (CASS) randomized trial. N Engl J Med. 1984;310:750–8.

  50. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data. Circulation. 1983;68:939–50.

  51. King SB III, Lembo NJ, Weintraub WS, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). N Engl J Med. 1994;331:1044–50.

    Article  PubMed  Google Scholar 

  52. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287:2542–51.

  53. Kuntz KM, Fleischmann KE, Hunink MG, Douglas PS. Cost-effectiveness of diagnostic strategies for patients with chest pain. Ann Intern Med. 1999;130:709–18.

    PubMed  CAS  Google Scholar 

  54. Lave JR, Pashos CL, Anderson GF, et al. Costing medical care: using Medicare administrative data. Med Care. 1994;32:JS77-JS89.

    Article  PubMed  CAS  Google Scholar 

  55. Stinnett AA, Mittleman MA, Weinstein MC, Kuntz KM, Cohen DJ, Williams LW. The cost-effectiveness of dietary and pharmacologic therapy for cholesterol reduction in adults. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996:349–91.

    Google Scholar 

  56. Russell MW, Huse DM, Drowns S, Hamel EC, Hartz SC. Direct medical costs of coronary artery disease in the United States. Am J Cardiol. 1998;81:1110–5.

    Article  PubMed  CAS  Google Scholar 

  57. Drug Topics Red Book. Montvale, NJ: Medical Economics Company, Inc; 1998.

  58. Drug Topics Red Book. Montvale, NJ: Medical Economics Company, Inc; 2003.

  59. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med. 1997;336:332–6.

    Article  PubMed  CAS  Google Scholar 

  60. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276:1253–8.

    Article  PubMed  CAS  Google Scholar 

  61. Nease RF Jr, Kneeland T, O’Connor GT, et al. Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team. JAMA. 1995;273:1185–90.

    Article  PubMed  Google Scholar 

  62. Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993;13:161–5.

    Article  PubMed  CAS  Google Scholar 

  63. Brown ML, Fintor L. Cost-effectiveness of breast cancer screening: preliminary results of a systematic review of the literature. Breast Cancer Res Treat. 1993;25:113–8.

    Article  PubMed  CAS  Google Scholar 

  64. Littenberg B, Garber AM, Sox HC Jr. Screening for hypertension. Ann Intern Med. 1990;112:192–202.

    Google Scholar 

  65. Coppleson LW, Brown B. The prevention of carcinoma of the cervix. Am J Obstet Gynecol. 1976;125:153–9.

    PubMed  CAS  Google Scholar 

  66. Fletcher RH, Fletcher SW, Wagner EH. Diagnosis. In: Satterfield TS, Taylor C, eds. Clinical Epidemiology. Philadelphia, Pa: Lippincott Williams & Wilkins; 1996:43–74.

    Google Scholar 

  67. Hunink M, Glasziou P, Siegel J, et al. Constrained Resources. Decision Making in Health and Medicine: Integrating Evidence and Values. Cambridge, UK: Cambridge University Press; 2001.

    Google Scholar 

  68. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823–8.

    PubMed  CAS  Google Scholar 

  69. Mak KH, Moliterno DJ, Granger CB, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1997;30:171–9.

    Article  PubMed  CAS  Google Scholar 

  70. Bacci S, Villella M, Villella A, et al. Screening for silent myocardial ischaemia in type 2 diabetic patients with additional atherogenic risk factors: applicability and accuracy of the exercise stress test. Eur J Endocrinol. 2002;147:649–54.

    Article  PubMed  CAS  Google Scholar 

  71. Cohn PF, Fox KM, Daly C. Silent myocardial ischemia. Circulation. 2003;108:1263–77.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Medicine and Clinical Epidemiology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, 606-8507, Kyoto, Japan

    Yasuaki Hayashino MD, MPH, Sizuko Nagata-Kobayashi MD, Takeshi Morimoto MD, MPH, Kenji Maeda MD, Takuro Shimbo MD & Tsuguya Fukui MD, MPH

Authors
  1. Yasuaki Hayashino MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sizuko Nagata-Kobayashi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takeshi Morimoto MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenji Maeda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takuro Shimbo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tsuguya Fukui MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasuaki Hayashino MD, MPH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hayashino, Y., Nagata-Kobayashi, S., Morimoto, T. et al. Cost-effectiveness of screening for coronary artery disease in asymptomatic patients with type 2 diabetes and additional atherogenic risk factors. J GEN INTERN MED 19, 1181–1191 (2004). https://doi.org/10.1111/j.1525-1497.2004.40012.x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1111/j.1525-1497.2004.40012.x

Key words

Search

Navigation